TELA Bio, Inc. filings document a commercial-stage medical technology business centered on soft-tissue reconstruction and the OviTex product portfolio for hernia repair and abdominal wall reconstruction. Form 8-K reports cover operating and financial results, revenue updates, Regulation FD disclosures, material agreements, debt and equity capital structure, and other material events tied to the company's medical technology operations.
Proxy materials and governance-related 8-Ks record board composition, director appointments and resignations, executive compensation matters, stockholder meeting proposals, inducement and equity-award practices, and Nasdaq listing-compliance disclosures for TELA common stock listed on the Nasdaq Global Market.
TELA Bio reported an insider update: a director filed a Form 3 initial statement of beneficial ownership.
The filing states no securities are beneficially owned as of the event date of 10/31/2025. The form was filed by one reporting person under Section 16.
TELA Bio expanded its Board of Directors from six to seven members and appointed William Plovanic as a Class I director, with his term expiring at the 2026 Annual Meeting of Stockholders. The Board determined he is an independent director under Nasdaq rules.
Plovanic, 56, brings experience as Managing Director of Healthcare Equity Research at Canaccord Genuity and prior leadership roles at Obalon Therapeutics. Upon appointment, he received an initial equity award consisting of an option to purchase 17,550 shares vesting in 36 equal monthly installments and 11,925 RSUs vesting in three equal annual installments, granted under the company’s 2019 Equity Incentive Plan. He will receive a $45,000 annual cash retainer for Board service. Beginning at the 2026 Annual Meeting, his annual equity awards will include options for 11,700 shares and 7,950 RSUs, each vesting on the earlier of one year from grant, the next annual meeting, or a change in control, subject to continued service.
Reporting person: Betty Jo Rocchio, a director at TELA Bio, Inc. (TELA), reported securities awards received on 10/09/2025 and the filing was signed on 10/10/2025.
The report shows 11,925 restricted stock units (RSUs) granted with zero purchase price; these RSUs vest in three equal annual installments beginning on 10/09/2026, subject to continued service. The filing also reports a stock option to buy 17,550 shares with an exercise price of $1.48, granted on 10/09/2025, vesting monthly over 36 months and expiring on 10/09/2035.
TELA Bio director Betty Jo Rocchio filed an initial Form 3 reporting no securities beneficially owned as of 10/09/2025. The filing lists her relationship to the issuer as a director and was signed by an attorney-in-fact on 10/10/2025. No non-derivative or derivative holdings are reported and Exhibit 24 (Power of Attorney) is attached.
TELA Bio reported a change in its board of directors. On October 4, 2025, director Lisa Colleran resigned from the Board and from the Nominating and Corporate Governance and Audit Committees, and her resignation was not due to any disagreement with the company’s operations, policies, or practices.
On October 7, 2025, the Board appointed Dr. Betty Jo Rocchio as a Class I director, effective October 9, 2025, with a term running until the 2026 annual meeting. She is an experienced senior nursing executive and has been deemed an independent director under Nasdaq rules, with no related-party or family relationships disclosed.
In connection with her appointment, Dr. Rocchio received an initial equity package of an option for 17,550 shares and 11,925 restricted stock units, vesting over three years, plus an annual cash retainer of $45,000. Beginning with the 2026 annual meeting, she is eligible for recurring annual equity awards of options for 11,700 shares and 7,950 restricted stock units, subject to continued service.
Laurence W. Lytton reports beneficial ownership of 3,424,191 shares of TELA Bio common stock, representing 8.5% of the outstanding class based on 39,616,440 shares. The position consists of 2,724,191 shares of common stock and 700,000 shares issuable upon exercise of outstanding warrants. The filing states the reporting person has sole voting power and sole dispositive power over all reported shares.
The filer certified the securities were not acquired to change or influence control of the issuer, indicating this disclosure reflects a substantial passive stake. The inclusion of warrants means the economic exposure and potential future share count may change if those instruments are exercised.
TELA Bio filed a Form S-8 to register 3,500,000 additional shares of common stock under its Amended and Restated 2019 Equity Incentive Plan. The board adopted an amendment and the company’s stockholders approved it, and this filing registers the Additional Shares for issuance under the Amended Equity Plan. After this increase, a total of 7,432,620 shares are registered for issuance under the plan. The filing incorporates prior S-8 registration statements by reference and attaches the Amended Equity Plan and related exhibits.
TELA Bio reported continued commercial growth with revenue of $20.2 million for the quarter ended June 30, 2025, a 26% increase from $16.1 million a year earlier, and $38.7 million for the six months, up 18% year-over-year. Gross profit for the quarter was $14.1 million. Quarterly net loss narrowed to $9.9 million (EPS -$0.22) from $12.6 million, while the six-month net loss was $21.2 million versus $18.3 million, noting the prior-year six-months included a $7.6 million gain on the sale of the NIVIS product line.
Balance sheet and liquidity show $34.98 million in cash and cash equivalents (restricted cash brings cash per statements of cash flows to $35.24 million), total assets of $67.54 million and total liabilities of $58.35 million. The company carries total debt of $41.38 million (long-term portion $38.05 million) under a MidCap term loan maturing in 2027 with covenants including minimum net revenue tests. Product mix for the quarter was $12.49 million OviTex and $7.33 million OviTex PRS, with international sales of $3.0 million. The company discloses an accumulated deficit of $379.9 million and says it expects to incur losses for the foreseeable future.
TELA Bio, Inc. furnished a press release reporting its financial results for the quarter ended June 30, 2025 and provided an updated corporate slide deck for investor meetings. The Form 8-K identifies the relevant disclosure items as Item 2.02 (results of operations and financial condition) and Item 7.01 (Regulation FD disclosure), and lists exhibits including the press release (Exhibit 99.1), the slide deck (Exhibit 99.2) and the Inline XBRL cover page (Exhibit 104). The filing notes these materials are furnished, not filed, and the document is signed by CEO Antony Koblish. The company’s common stock trades on Nasdaq under the symbol TELA and the registrant indicates emerging growth company status.